Coronary Artery Disease

Coronary Artery Disease
Cardiovascular disease (CVD) is the leading cause of death and disability in the developed countries. According to the American Heart Association, CVD claims more lives in the US than the next four leading causes of death combined, which include cancer, respiratory disease, accidents, and diabetes (AHA report 2016). Coronary artery disease (CAD) is the single largest killer in the US, causing 450,000 deaths annually. CAD results in from atherosclerosis in one or more of the arteries that supply blood to the heart, leading to accumulation of plaque on the arteries walls and eventually to obstruction to blood flow.
Read More
This result is in line with a large scale study (Patel MR et. al. Am Heart J. 2014;167:846–52.e2.), which found that 58.4% of 661,063 patients with suspected coronary artery disease referred to cardiac catheterization at 1,128 US hospitals between 2009 and 2011 had no obstructive coronary disease (defined as >50% stenosis). 40.1% of the patients did not have CAD at all.
Further, most of the patients in that study underwent non-invasive “functional” tests (most commonly SPECT) prior to catheterization. Still, 53.4% of the patients who had a positive functional test result did not have obstructive CAD. On the other hand, 30.0% of the patients who had negative functional test results did have obstructive CAD. Thus, for that huge study population, functional testing had a very limited value in the pre-selection of patients for catheterization.
Diagnostic catheterizations are invasive procedures that involve pain, fairly high radiation dosage, hospitalization, certain risk and cost to the health system. Therefore, there is a need for non-invasive, low dose, efficient and accurate CAD diagnostics.
